Pulnovo Medical Limited, a globally recognized device pioneer in the treatment of Pulmonary Hypertension (PH) and Heart Failure (HF),recently announced the official release of the "Chinese Expert Consensus on Percutaneous Pulmonary Artery Denervation (PADN) for Pulmonary Arterial Hypertension". This marks a significant milestone following the inclusion of PADN in the esteemed "2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension" last year.

This newly published consensus is a testament to the collective expertise and experience of numerous leading experts in China. It provides a comprehensive and systematic overview of the treatment principles, indications, procedural techniques, and postoperative management associated with PADN. The primary aim of this consensus is to offer clinicians an authoritative reference guide to improve patient outcomes and advance the treatment of pulmonary arterial hypertension.

Pulmonary Arterial Hypertension (PAH) remains a challenging condition to treat, necessitating continuous advancements in therapeutic approaches. PADN represents a breakthrough in the interventional treatment of PAH, offering a novel method to alleviate symptoms and enhance patients' quality of life. The inclusion of PADN in these guidelines reflects its importance and the positive impact it has on PAH management.

About PADN

Pulmonary Artery Denervation (PADN) is a percutaneous pulmonary artery intervention procedure that uses a PADN catheter to deliver radiofrequency energy to the sympathetic nerves in the outer membrane of the pulmonary artery, resulting in the disappearance of the myelin sheath of the nerves and the fusion of the axons, which inhibits sympathetic activity, increases cardiac output, reduces pulmonary artery pressure , inhibits the pathologic remodeling of the pulmonary arteries, improves the patient's exercise endurance and cardiac function, and achieves long-term benefits from a single minimally invasive procedure.

About Pulnovo Medical

Pulnovo Medical Limited, is a globally recognized device pioneer in the treatment for pulmonary hypertension and heart failure. Established in 2013 and rooted in innovation, Pulnovo Medical is committed to leveraging our deep expertise in the science of breakthrough technologie with the goal to market our innovative therapeutic solutions and benefit patients around the world.